CING

Cingulate Inc. Common Stock

4.26

USD

+0.02

+0.47%

Nov 06, 15:58 UTC -5

Closed

After-Market

4.24

-0.02

-0.38%

Cingulate Inc. Common Stock (CING) Earnings

CING Earnings Reports

Positive Surprise Ratio

CING beat 8 of 19 last estimates.

42%

Next Report

Date of Next Report

Estimate for Q-- -- (Revenue/ EPS)

Implied change from Q2 26 (Revenue/ EPS)

Implied change from Q-- -- (Revenue/ EPS)

Cingulate Inc. Common Stock earnings per share and revenue

On Aug 13, 2026, CING reported earnings of -0.45 USD per share (EPS) for Q2 26, beating the estimate of -0.63 USD, resulting in a 29.41% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -4.22% price change (close before vs. close after earnings).

Looking ahead to -- --, -- analysts forecast an EPS of -- USD, with revenue projected to reach -- USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.

Industry Peers’ Earnings

Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.

Immunocore Holdings plc - ADR

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.13

Actual

-$0.28

Surprise

-104.08%

Entera Bio Ltd. Ordinary Shares

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.06

Actual

-$0.11

Surprise

-58.50%

Vogenx Inc Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.16

Actual

-$0.47

Surprise

-187.99%

Agenus Inc.

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.27

Actual

$0.02

Surprise

+107.26%

Anika Therapeutics Inc

Report Date

Nov 06, 2026 For Q3 26

Estimate

$0.06

Actual

-$0.02

Surprise

-132.68%

Moderna, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$1.27

Actual

$0.38

Surprise

+129.79%

Bio-Techne Corp.

Report Date

Nov 06, 2026 For Q1 27

Estimate

$0.44

Actual

$0.44

Surprise

-1.96%

Aligos Therapeutics, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$2.21

Actual

-$2.09

Surprise

+5.58%

CervoMed Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.49

Actual

-$0.39

Surprise

+21.97%

Creative Medical Technology Holdings, Inc. Common Stock

Report Date

Nov 06, 2026 For Q3 26

Estimate

-$0.24

Actual

-$0.40

Surprise

-63.40%

FAQ

What were Cingulate Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?

For Q2 2026, Cingulate Inc. Common Stock reported EPS of -$0.45, beating estimates by 29.41%, and revenue of $0.00, 0% as expectations.

How did the market react to Cingulate Inc. Common Stock's Q2 2026 earnings?

The stock price moved down -4.22%, changed from $5.21 before the earnings release to $4.99 the day after.

When is Cingulate Inc. Common Stock expected to report next?

The next earning report is scheduled for --.

What are the forecasts for Cingulate Inc. Common Stock's next earnings report?

Based on -- analysts, Cingulate Inc. Common Stock is expected to report EPS of -- and revenue of -- for Q-- --.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.